论文部分内容阅读
目的探讨多肿瘤标志物蛋白芯片在肺癌诊疗中的应用价值。方法采用多肿瘤标志物蛋白芯片检测肺癌患者157例、良性肺病177例、健康体检者41例血清中的12种肿瘤标志物(CA125、CA19-9、Ferritin、CA153、CA242、CEA、AFP、NSE、PSA、f-PSA、HGH、β-HCG)。结果肺癌组肿瘤标记物阳性率为92.36%,良性肺病组为76.83%,健康对照组为7.32%,差异有统计学意义(P<0.01)。肺癌组血清中肿瘤标记物CEA、CA242阳性率与良性肺病组、健康对照组比较,差异均有统计学意义(均P<0.05),而β-HCG、AFP、f-PSA、PSA、HGH等差异无统计学意义(均P>0.05)。肺癌组血清中肿瘤标记物CA19-9、NSE、CEA、CA242、CA125、CA153水平显著高于肺良性病变组和健康对照组(均P<0.05),而β-HCG、f-PSA、PSA、HGH等差异无统计学意义(P>0.05)。结论多肿瘤标志物蛋白芯片仅可用于肺癌的早期辅助诊断,并不能作为肺癌的确诊指标。
Objective To investigate the value of multiple tumor marker protein chip in diagnosis and treatment of lung cancer. Methods Tumor markers (CA125, CA19-9, Ferritin, CA153, CA242, CEA, AFP, NSE) were detected in 157 patients with lung cancer, 177 with benign lung disease, , PSA, f-PSA, HGH, β-HCG). Results The positive rate of tumor markers was 92.36% in lung cancer group, 76.83% in benign lung disease group and 7.32% in healthy control group, with significant difference (P <0.01). The positive rates of CEA and CA242 in lung cancer group were significantly higher than those in benign lung disease group and healthy control group (all P <0.05), while β-HCG, AFP, f-PSA, PSA and HGH The difference was not statistically significant (all P> 0.05). The levels of tumor markers CA19-9, NSE, CEA, CA242, CA125 and CA153 in lung cancer group were significantly higher than those in benign lung disease group and healthy control group (all P <0.05) HGH and other differences was not statistically significant (P> 0.05). Conclusion Multi-tumor marker protein chip can only be used for early diagnosis of lung cancer, and can not be used as a diagnostic indicator of lung cancer.